A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: An opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology

Giuseppina Novo, Alessia Pepe, Carlo G. Tocchetti, Concetta Zito, Nicola Maurea, Rosalinda Madonna, Paolo Spallarossa, Pasquale Pagliaro, Giuseppe Mercuro, Donato Mele, Alessia Pepe, Ines Monte, Christian Cadeddu

Risultato della ricerca: Article

17 Citazioni (Scopus)

Abstract

The US National Cancer Institute estimates that cardiotoxicity (CTX) from target therapy refers mostly to four groups of drugs: epidermal growth factor receptor 2 inhibitors, angiogenic inhibitors, directed Abelson murine leukemia viral oncogene homolog inhibitors, and proteasome inhibitors. The main cardiotoxic side-effects related to antiepidermal growth factor receptor 2 therapy are left ventricular systolic dysfunction and heart failure. Angiogenesis inhibitors are associated with hypertension, left ventricular dysfunction/heart failure, myocardial ischemia, QT prolongation, and thrombosis. Moreover, other agents may be related to CTX induced by treatment. In this study, we review the guidelines for a practical approach for the management of CTX in patients under anticancer target therapy.
Lingua originaleEnglish
pagine (da-a)93-104
Numero di pagine12
RivistaJournal of Cardiovascular Medicine
Volume17
Stato di pubblicazionePublished - 2016

Fingerprint

Angiogenesis Inhibitors
Cardiology
Left Ventricular Dysfunction
Pharmaceutical Preparations
Systolic Heart Failure
Proteasome Inhibitors
Growth Factor Receptors
National Cancer Institute (U.S.)
Therapeutics
Oncogenes
Epidermal Growth Factor Receptor
Myocardial Ischemia
Leukemia
Thrombosis
Heart Failure
Guidelines
Hypertension
Cardiotoxicity

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cita questo

A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: An opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. / Novo, Giuseppina; Pepe, Alessia; Tocchetti, Carlo G.; Zito, Concetta; Maurea, Nicola; Madonna, Rosalinda; Spallarossa, Paolo; Pagliaro, Pasquale; Mercuro, Giuseppe; Mele, Donato; Pepe, Alessia; Monte, Ines; Cadeddu, Christian.

In: Journal of Cardiovascular Medicine, Vol. 17, 2016, pag. 93-104.

Risultato della ricerca: Article

Novo, Giuseppina ; Pepe, Alessia ; Tocchetti, Carlo G. ; Zito, Concetta ; Maurea, Nicola ; Madonna, Rosalinda ; Spallarossa, Paolo ; Pagliaro, Pasquale ; Mercuro, Giuseppe ; Mele, Donato ; Pepe, Alessia ; Monte, Ines ; Cadeddu, Christian. / A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: An opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. In: Journal of Cardiovascular Medicine. 2016 ; Vol. 17. pagg. 93-104.
@article{3f49ccc80745402ea1a7d7d1af9f3eef,
title = "A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: An opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology",
abstract = "The US National Cancer Institute estimates that cardiotoxicity (CTX) from target therapy refers mostly to four groups of drugs: epidermal growth factor receptor 2 inhibitors, angiogenic inhibitors, directed Abelson murine leukemia viral oncogene homolog inhibitors, and proteasome inhibitors. The main cardiotoxic side-effects related to antiepidermal growth factor receptor 2 therapy are left ventricular systolic dysfunction and heart failure. Angiogenesis inhibitors are associated with hypertension, left ventricular dysfunction/heart failure, myocardial ischemia, QT prolongation, and thrombosis. Moreover, other agents may be related to CTX induced by treatment. In this study, we review the guidelines for a practical approach for the management of CTX in patients under anticancer target therapy.",
keywords = "angiogenesis inhibitors; HER2/epidermal growth factor receptor 2; tyrosine kinase inhibitors; Cardiology and Cardiovascular Medicine",
author = "Giuseppina Novo and Alessia Pepe and Tocchetti, {Carlo G.} and Concetta Zito and Nicola Maurea and Rosalinda Madonna and Paolo Spallarossa and Pasquale Pagliaro and Giuseppe Mercuro and Donato Mele and Alessia Pepe and Ines Monte and Christian Cadeddu",
year = "2016",
language = "English",
volume = "17",
pages = "93--104",
journal = "Journal of Cardiovascular Medicine",
issn = "1558-2027",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: An opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology

AU - Novo, Giuseppina

AU - Pepe, Alessia

AU - Tocchetti, Carlo G.

AU - Zito, Concetta

AU - Maurea, Nicola

AU - Madonna, Rosalinda

AU - Spallarossa, Paolo

AU - Pagliaro, Pasquale

AU - Mercuro, Giuseppe

AU - Mele, Donato

AU - Pepe, Alessia

AU - Monte, Ines

AU - Cadeddu, Christian

PY - 2016

Y1 - 2016

N2 - The US National Cancer Institute estimates that cardiotoxicity (CTX) from target therapy refers mostly to four groups of drugs: epidermal growth factor receptor 2 inhibitors, angiogenic inhibitors, directed Abelson murine leukemia viral oncogene homolog inhibitors, and proteasome inhibitors. The main cardiotoxic side-effects related to antiepidermal growth factor receptor 2 therapy are left ventricular systolic dysfunction and heart failure. Angiogenesis inhibitors are associated with hypertension, left ventricular dysfunction/heart failure, myocardial ischemia, QT prolongation, and thrombosis. Moreover, other agents may be related to CTX induced by treatment. In this study, we review the guidelines for a practical approach for the management of CTX in patients under anticancer target therapy.

AB - The US National Cancer Institute estimates that cardiotoxicity (CTX) from target therapy refers mostly to four groups of drugs: epidermal growth factor receptor 2 inhibitors, angiogenic inhibitors, directed Abelson murine leukemia viral oncogene homolog inhibitors, and proteasome inhibitors. The main cardiotoxic side-effects related to antiepidermal growth factor receptor 2 therapy are left ventricular systolic dysfunction and heart failure. Angiogenesis inhibitors are associated with hypertension, left ventricular dysfunction/heart failure, myocardial ischemia, QT prolongation, and thrombosis. Moreover, other agents may be related to CTX induced by treatment. In this study, we review the guidelines for a practical approach for the management of CTX in patients under anticancer target therapy.

KW - angiogenesis inhibitors; HER2/epidermal growth factor receptor 2; tyrosine kinase inhibitors; Cardiology and Cardiovascular Medicine

UR - http://hdl.handle.net/10447/195398

UR - http://journals.lww.com/jcardiovascularmedicine

M3 - Article

VL - 17

SP - 93

EP - 104

JO - Journal of Cardiovascular Medicine

JF - Journal of Cardiovascular Medicine

SN - 1558-2027

ER -